Search research articles
Contact Us
Filters
Showing results (51-60 of 60) with videos related to
Page
of 6
Sort By:
You have reached the last page of results.
This site can display upto 60 results.
Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners
|
February 22, 2022
Day 4 vs. day 12 G-CSF administration following reduced intensity peripheral blood allogeneic stem cell transplant
Rachel V Hatch, Craig W Freyer, Alison Carulli, et al.
European Journal of Haematology
|
December 27, 2024
Tumor Lysis Syndrome in Acute Myeloid Leukemia Patients Treated With a Venetoclax Based Regimen
Margaret Rowe, Daria Babushok, Martin Carroll, et al.
The Prostate
|
January 16, 2016
AXIN2 expression predicts prostate cancer recurrence and regulates invasion and tumor growth
Brian R Hu, Adrian S Fairey, Anisha Madhav, et al.
Leukemia & Lymphoma
|
February 21, 2022
Letermovir vs. high-dose valacyclovir for cytomegalovirus prophylaxis following haploidentical or mismatched unrelated donor allogeneic hematopoietic cell transplantation receiving post-transplant cyclophosphamide
Craig W Freyer, Alison Carulli, Shannon Gier, et al.
Transplantation and Cellular Therapy
|
May 9, 2021
Leucovorin Rescue After Methotrexate Graft-Versus-Host Disease Prophylaxis Shortens the Duration of Mucositis, Time to Neutrophil Engraftment, and Hospital Length of Stay
Craig W Freyer, Shannon Gier, Mary E Moyer, et al.
Blood Advances
|
January 31, 2025
Evolving racial/ethnic disparities in AML survival in the novel therapy era
Xin Wang, Phyllis A Gimotty, Andrew H Matthews, et al.
Transplantation and Cellular Therapy
|
November 6, 2022
Clofarabine and Busulfan Myeloablative Conditioning in Allogeneic Hematopoietic Cell Transplantation for Patients With Active Myeloid Malignancies
Matthew P Connor, Alison W Loren, Elizabeth O Hexner, et al.
Blood Advances
|
May 4, 2022
Real-world effectiveness of CPX-351 vs venetoclax and azacitidine in acute myeloid leukemia
Andrew H Matthews, Alexander E Perl, Selina M Luger, et al.
American Journal of Hematology
|
June 19, 2023
Real-world effectiveness of intensive chemotherapy with 7&3 versus venetoclax and hypomethylating agent in acute myeloid leukemia
Andrew H Matthews, Alexander E Perl, Selina M Luger, et al.
Nature Medicine
|
September 27, 2024
Cytokine-mediated CAR T therapy resistance in AML
Anand S Bhagwat, Leonel Torres, Olga Shestova, et al.
Page
of 6
Search research articles
Search
Showing results (51-60 of 60) with videos related to
Sort By:
Page
of 6
You have reached the last page of results.
This site can display upto 60 results.
Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners
|
February 22, 2022
Day 4 vs. day 12 G-CSF administration following reduced intensity peripheral blood allogeneic stem cell transplant
Rachel V Hatch, Craig W Freyer, Alison Carulli, et al.
European Journal of Haematology
|
December 27, 2024
Tumor Lysis Syndrome in Acute Myeloid Leukemia Patients Treated With a Venetoclax Based Regimen
Margaret Rowe, Daria Babushok, Martin Carroll, et al.
The Prostate
|
January 16, 2016
AXIN2 expression predicts prostate cancer recurrence and regulates invasion and tumor growth
Brian R Hu, Adrian S Fairey, Anisha Madhav, et al.
Leukemia & Lymphoma
|
February 21, 2022
Letermovir vs. high-dose valacyclovir for cytomegalovirus prophylaxis following haploidentical or mismatched unrelated donor allogeneic hematopoietic cell transplantation receiving post-transplant cyclophosphamide
Craig W Freyer, Alison Carulli, Shannon Gier, et al.
Transplantation and Cellular Therapy
|
May 9, 2021
Leucovorin Rescue After Methotrexate Graft-Versus-Host Disease Prophylaxis Shortens the Duration of Mucositis, Time to Neutrophil Engraftment, and Hospital Length of Stay
Craig W Freyer, Shannon Gier, Mary E Moyer, et al.
Blood Advances
|
January 31, 2025
Evolving racial/ethnic disparities in AML survival in the novel therapy era
Xin Wang, Phyllis A Gimotty, Andrew H Matthews, et al.
Transplantation and Cellular Therapy
|
November 6, 2022
Clofarabine and Busulfan Myeloablative Conditioning in Allogeneic Hematopoietic Cell Transplantation for Patients With Active Myeloid Malignancies
Matthew P Connor, Alison W Loren, Elizabeth O Hexner, et al.
Blood Advances
|
May 4, 2022
Real-world effectiveness of CPX-351 vs venetoclax and azacitidine in acute myeloid leukemia
Andrew H Matthews, Alexander E Perl, Selina M Luger, et al.
American Journal of Hematology
|
June 19, 2023
Real-world effectiveness of intensive chemotherapy with 7&3 versus venetoclax and hypomethylating agent in acute myeloid leukemia
Andrew H Matthews, Alexander E Perl, Selina M Luger, et al.
Nature Medicine
|
September 27, 2024
Cytokine-mediated CAR T therapy resistance in AML
Anand S Bhagwat, Leonel Torres, Olga Shestova, et al.
Page
of 6